Scancell Holdings plc
LSE SCLP.L
Scancell Holdings plc Return on Capital Employed (ROCE) for the year ending April 30, 2024
-
Scancell Holdings plc Return on Capital Employed (ROCE) for the year ending April 30, 2023 was -48.49%, a -404.44% change year over year.
-
Scancell Holdings plc Return on Capital Employed (ROCE) for the year ending April 30, 2022 was -9.61%, a 95.15% change year over year.
-
Scancell Holdings plc Return on Capital Employed (ROCE) for the year ending April 30, 2021 was -198.14%, a -173.35% change year over year.
-
Scancell Holdings plc Return on Capital Employed (ROCE) for the year ending April 30, 2020 was -72.49%.
| Date | Return on Capital Employed (ROCE) | Interest Coverage Ratio | Debt to Equity Ratio | Return on Common Equity |
|---|
Don’t Miss A Beat
| CEO | Dr. Phillip John L'Huillier |
| IPO Date | Feb. 12, 2010 |
| Location | United Kingdom |
| Headquarters | Unit 202 Bellhouse Building |
| Employees | 61 |
| Sector | Healthcare |
| Industries | |
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 for the treatment of non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.
Past 5 years
USD 0.06
USD 0.03
USD 0.59
StockViz Staff
February 5, 2025
Any question? Send us an email